Drugs / Pneumococcal vaccine (13-valent)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03547271 | Dec 2018 → May 2023 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal vaccine (13-valent) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547271 ↗ |
| Modality | Vaccine | “Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)” NCT03547271 ↗ |